Minor Histocompatibility Antigens

Allelic alloantigens often responsible for weak graft rejection in cases when (major) histocompatibility has been established by standard tests. In the mouse they are coded by more than 500 genes at up to 30 minor histocompatibility loci. The most well-known minor histocompatibility antigen in mammals is the H-Y antigen.

Also Known As:

Networked: 266 relevant articles (4 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Falkenburg, J H Frederik: 20 articles (05/2015 - 01/2003)
2.	Dolstra, Harry: 13 articles (05/2015 - 10/2002)
3.	Goulmy, Els: 13 articles (01/2015 - 08/2002)
4.	Kester, Michel G D: 11 articles (05/2015 - 03/2003)
5.	Riddell, Stanley R: 10 articles (03/2011 - 08/2002)
6.	Fredrix, Hanny: 8 articles (05/2015 - 10/2002)
7.	Willemze, Roel: 8 articles (10/2009 - 03/2003)
8.	Korngold, Robert: 7 articles (06/2015 - 12/2003)
9.	van der Voort, Robbert: 7 articles (05/2015 - 03/2009)
10.	Heemskerk, Mirjam H M: 7 articles (05/2015 - 03/2003)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2015 - "The therapeutic efficacy is based on donor-derived CD8(+) T cells that recognize minor histocompatibility antigens (MiHAs) expressed by patient's tumor cells. " 07/15/2009 - "New studies show that tumor-reactive T cells are directed against diverse tumor-specific targets as well as minor histocompatibility antigens." 03/19/2009 - "Targeting minor histocompatibility antigens (mHags) with hematopoiesis- and cancer-restricted expression, for example, HA-1, may allow boosting the antitumor effect of allogeneic SCT without risking severe GVHD. " 06/01/2008 - "Thus, it is crucial to identify minor histocompatibility antigens (mHags) only expressed in tumor cells but not GVHD target organs. " 05/01/2008 - "Here we review a number of approaches currently under investigation to specifically augment GVT effects, including the identification of minor histocompatibility antigens (mHA), adoptive immunotherapy with tumor-specific or mHA-specific cytotoxic T lymphocytes, vaccination of the donor or recipient to stimulate tumor-specific immunity, and adoptive transfer of natural killer cells. "
2.	Graft vs Host Disease (Graft-Versus-Host Disease) 04/01/2005 - "Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission." 01/01/1988 - "A well-characterized murine model of graft-vs-host disease (GVHD) that develops in response to minor histocompatibility antigens was used to study the mechanism of an immunodeficiency syndrome that is associated with GVHD. " 08/01/1987 - "We have used a cell-wall-deficient mutant of Escherichia coli (E coli J5) to study the effect of active and passive immunization against bacterial endotoxin (ET) in a murine model of acute graft-versus-host disease (GVHD) induced by minor histocompatibility antigens. " 09/26/2013 - "Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease." 12/01/2009 - "However, graft-versus-host disease (GVHD), which is initiated by alloreactive donor T cells that recognize mismatched major and/or minor histocompatibility antigens and cause severe damage to hematopoietic and epithelial tissues, is a potentially lethal complication of allogeneic BMT. "
3.	Leukemia 01/01/2015 - "This clinical complication has brought about a huge research effort that led to the development of leukemia-specific T-cell therapy aiming at the direct recognition of leukemia-specific rather than minor histocompatibility antigens. " 04/01/2014 - "CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT." 03/01/2011 - "Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia." 03/04/2003 - "Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia." 10/01/1999 - "Although currently minor histocompatibility antigens appear to be the most likely targets for DLI, several groups are focusing on the generation of leukemia-specific immunity. "
4.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 07/20/1999 - "We report that CD8(+) cytotoxic T lymphocyte (CTL) clones specific for minor histocompatibility antigens inhibit the engraftment of human acute myeloid leukemia cells in nonobese diabetic/SCID mice and demonstrate that this inhibition is mediated by direct CTL recognition of SCID leukemia-initiating cells. " 03/01/1995 - "A murine model for acute myeloid leukemia (mAML) was used to study graft-vs.-leukemia (GVL) effects on residual leukemic cells across both major (MHC) and minor histocompatibility antigens (mHA) barriers. " 09/01/1998 - "CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens."
5.	Mastocytoma 03/01/1985 - "In previous studies it was found that BALB/c (H-2d) was more susceptible than (BALB/c X A)F1 (H-2d X H-2a) to a tumor bearing multiple mismatched minor histocompatibility antigens, the DBA/2 (H-2d) mastocytoma P815, and that this resistance was H-2 linked. " 10/01/1999 - "Mutant p53-expressing syngeneic, nontumor forming BALB/c 3T3 fibroblasts, tumor forming ras-transfected BALB/c 3T3 sarcomas, and DBA/2-derived P815 mastocytoma cells, which differ at the level of minor histocompatibility antigens, were used as cellular vaccines. "

Related Drugs and Biologics

1.	16-iodo-3-methylhexadecanoic acid (MIHA)
2.	Chloroquine (Aralen)
3.	Histocompatibility Antigens (Histocompatibility Antigen)
4.	Antigens
5.	T-Cell Antigen Receptors (T-Cell Receptor)
6.	Peptides
7.	Vaccines
8.	Cytokines
9.	Isoantigens (Alloantigen)
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Immunotherapy
3.	Cell Transplantation
4.	Stem Cell Transplantation
5.	Bone Marrow Transplantation (Transplantation, Bone Marrow)